FGL2 and metabolic dysfunction-associated steatohepatitis: These data demonstrated that fgl2 upregulated Fasn and SREBP-2, which contribute to lipogenesis, but downregulated PPARα and CPT1A, which enhance lipolysis, particularly in HFD-induced NASH.